Venous UlcerNCT00847002
Flexitouch Treatment for Venous Ulcers
A study testing Standard Wound Care and Flexitouch System with Standard Wound Care in people with Venous Ulcer, run by Tactile Systems Technology, Inc. at 2 sites in United States.
Trial summary
This is a study to compare the healing process of venous stasis ulcers when the Flexitouch® system is added to the standard treatment of venous ulcers. We hypothesize that adding the Flexitouch® system to standard venous ulcer treatment will result in 1. greater complete healing 2. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Venous Ulcer
- What is being tested?
- Standard Wound Care and Flexitouch System with Standard Wound Care
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 8 participants
- Where
- 2 sitesUnited States
- Study dates
- Sep 2007to Aug 2010
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient must be at least 18 years old
- The ulcer maximum length x its maximum width must be greater or equal to 0 cm2
- The ulcer must extend through both the epidermis and dermis, with no exposed tendon or bone.
- The ulcer must have been present for more than 1 month.
- The ulcer must be located below the knee.
- The ulcer bed must have some viable tissues with some granulation tissue.
Who cannot join
- Exposed bone, tendon, or fascia
- Severe rheumatoid arthritis
- History of radiotherapy to the ulcer site
- Uncontrolled congestive heart failure
- Receiving corticosteroids or immune suppressive therapy
- History of collagen vascular disease
Show all 21Show fewer
- Known malnutrition (albumin<3.0 g/dL). If malnutrition is suspected, the albumin level should be checked to determine if the patient meets the albumin criterion.
- The ulcer is clinically infected. However, patients may be entered into the study after successful treatment of infection.
- Known uncontrolled diabetes (HgbA1c > 8%). If uncontrolled diabetes is suspected, the Hgb A1c should be checked to determine patient eligibility.
- Signs of cellulitis, osteomyelitis, or necrotic or avascular ulcer bed(s).
- Known arterial insufficiency (Ankle-brachial index < 0.7, or TcPO2 < 35 mm Hg, or Toe-brachial index < 0.4). If peripheral vascular disease is suspected, vascular lab testing should be checked to determine patient eligibility.
- Active sickle cell disease
- Unable to comply with the procedures described in the protocol
- Enrolled in a clinical evaluation for another investigational wound-care device or drug
- Patients diagnosed with deep venous thrombosis or phlebitis in the affected limb in the last 6 months
- Pregnancy, suspected or confirmed
- Chronic renal disease, if deemed by the principal investigator to be severe enough to interfere with wound healing
- Known active or recurrent cancer, or currently receiving chemotherapy or radiation therapy
- History or pulmonary embolism
- Poorly controlled asthma
- Pulmonary Edema
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Wound Healing and Hyperbaric Center
College Station, Texas, 77845
VA Medical Center
Minneapolis, Minnesota, 55417
About this study
Official title: A Pilot Randomized Trial of Flexitouch as an Adjunctive Treatment for Venous Ulcers
This is a study to compare the healing process of venous stasis ulcers when the Flexitouch® system is added to the standard treatment of venous ulcers. We hypothesize that adding the Flexitouch® system to standard venous ulcer treatment will result in
- greater complete healing
- greater percentage reduction in ulcer area
- reduced time to complete healing, as compared to the use of standard treatment alone
- a greater reduction in affected leg volume as compared to standard treatment alone.
Read the detailed description
A pilot randomized trial of Flexitouch® as an adjunctive treatment for venous ulcers
Objectives To determine if the Flexitouch® compression therapy system, when added to standard venous ulcer (VU) treatment, results in: 1. Greater complete healing at 12 weeks as compared to standard treatment alone. 2. Greater percentage reduction in ulcer area at 12 weeks as compared to standard treatment alone. 3. Less time to complete healing as compared to standard treatment alone 4. A greater reduction in the leg volume of the affected leg
Hypothesis We hypothesize that adding the Flexitouch® system to standard venous ulcer treatment will result in
- greater complete healing, 2) greater percentage reduction in ulcer area 3) reduced time to complete healing, as compared to the use of standard treatment alone, and 4) a greater reduction in affected leg volume as compared to standard treatment alone.
Patient recruitment, eligibility, and exclusions Patients who present at our clinic with a venous leg ulcer, as judged by clinical presentation and history, will be recruited for participation in this research study. For this pilot study a total of 16 patients will be recruited.
Protocol and Procedures After verifying eligibility and administering an approved informed consent, patients will be randomized to one of the study arms (A or B). Study patients will be seen one or two times per week (per physician's discretion) for 12-weeks for standard wound care and treatment. For both groups, sustained compression will be achieved with the FarrowWrap™ Classic device. This device will be worn continuously except during the twice-weekly treatments and when Flexitouch therapy is being undertaken (Group B only). Group B will use Flexitouch at home every day (twice daily); Group A will not use Flexitouch. Once per week, treatment and parameter assessments will be undertaken as described below.
Standard Wound Care and Treatment Standard wound care treatment will include gentle wound ulcer cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (e.g Acticoat, Aquacel Ag, or Mepilex Ag foam dressings), reminding subjects of the importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle range of motion exercises through the day. The FarrowWrap Classic device is applied over the dressing to achieve suitable compression pressures as an important component of the standard treatment. For venous ulcer treatment it is applied at full stretch. The patient will be given instructions as to how to apply the FarrowWrap at home.
Flexitouch System and its Use Patients who have been randomized to Group B will be provided a home Flexitouch unit. They will be given instructions to use it on a twice daily basis. They will be instructed to remove the FarrowWrap during the time they are using Flexitouch. The Flexitouch System works by applying dynamic low-pressure compression to the trunk and affected limbs using gentle, rhythmic massage action. The system consists of a controller unit with four eight-port connectors and a garment set for the trunk and leg. The garments are placed around the trunk and affected limbs and are connected to the controller by a tubing harness. The controller inflates and deflates the air chambers within the garments in a pre-determined pattern to assist the lymphatics in moving the fluid into adjacent lymph node regions of the trunk. The controller inflates individual chambers in the garments for 1-3 seconds per inflation.
Potential Treatment modifications The patient's welfare, as determined by the principal investigator, will take precedence over any study procedures. Any interventions necessary for the patient's welfare will be undertaken as necessary.
Wound Photography The wound will be photographed using a digital camera with zoom capability supplied by the sponsor of this study. All photographs will be taken with the camera pointing directly down to the wound such that the angle between the camera and the plane-of-the wound is as near to 90o as possible. Flash will be avoided if there is adequate lighting. The vertical distance from the wound to the camera is not critical but a distance of about 20 cm will be used when possible. Prior to taking photographs, a suitable dimensional scale or calibration standard will be placed in contact with the skin near, but outside a wound margin. In the case of a one-dimensional scale, it will be placed above or below the wound, and positioned along the long dimension of the wound. A suitable calibration standard will be supplied by the sponsor of this study. The framing of the photo will be such as to include 1) the complete wound bed, 2) a small sampling of the surrounding periwound tissue and 3) the calibration standard or scale. The composed image, as viewed through the camera LCD viewport, will be as large as possible while still including the required elements. The camera will be oriented such that the horizontal dimension of the LCD viewport is parallel to the horizontal calibration scale on the leg.
Wound Tracing After photographing, the wound margins will be traced by placing a transparent grid over the wound. The grid is a commercial product (E-Z Graph) that is designed for this purpose. It consists of two layers; a bottom layer which is in contact with the wound and an upper layer on which tracing is done using a colored pen. The upper layer has a grid system with 1 x 1 cm squares imbedded into the material. After tracing the bottom layer is discarded. The patient's study ID, visit number and visit date are then recorded on a space provided on the upper tracing grid.
Assessment of Leg Volumes Leg volumes of both right and left legs from ankle to knee will be determined. This is done using a calibrated tape measure (Gulick-type) to measure circumferences at 4 cm intervals starting at the malleoulus and progressing toward the knee. From these circumference measurements, limb volumes will be determined using the well established truncated cone model together with a validated software algorithm. Using this method the wound assessor enters the circumferences into a standardized form and the appropriate volumes are automatically determined.
Assessment of Complete Wound Healing At each visit the wound will be carefully inspected by the Principal Investigator and the presence or absence of complete wound healing noted and recorded. For this study, wound healing will be considered to occur when the wound is fully covered with epithelium and there is no drainage. In addition, at each visit, a study-related case report form will be completed by the Principal Investigator to document various clinical features of the wound and to note any relevant study-related actions or events. This form will be embedded within password protected software so that most wound descriptors will be able to be entered and documented with a simple mouse click.
Analysis of Wound Areas and Related Parameters Wound Areas by Photo Images: The digital images of the wound will be coded by the Principal Investigator by suitably renaming each photographic image file with a unique identifier. He will keep a record of these coded file names and the group, patient, and visit date and number to which they correspond. A copy of each image file will be made and stored on a CD. The CD will be sent to a scientific advisor who works with the study sponsor. The advisor will be responsible for the analyses of the images, including the determination of wound areas via computerized planimetry and for subsequent data and statistical analyses. The analyst will blind as to which actual group the images correspond. At the completion of the data acquisition phase of the study, the analyst will be told which images belong to common groups, but he will still not know which of the common groups belong to which arm of the study. He will thus remain blind during the subsequent statistical analyses.
Wound Areas by Tracings: As a complementary comparison approach, wound areas will also be assessed from the wound tracings. The analyst will be supplied with copies of the coded tracings. The tracings will then be scanned and the wound areas determined by computerized digital planimetry as previously described. Areas determined by this method will serve as a check measurement and will be used as a backup in those cases (if any) in which photographic quality is inadequate.
Leg Volumes: In addition to photographs and tracings, the analyst will be supplied with coded electronic copies of the leg circumference forms. This data will be used to determine if, and to what extent, changes in leg volume or edema occur, and if there are differences in these parameters between groups A and B.
Wound Descriptors: A coded electronic version of the case report form, containing wound descriptor parameters data, will be supplied to the analyst. This information will be used primarily in the final analysis to summarize the clinical progression of the wounds.
- Conditions
- Venous Ulcer
- Being tested
- Standard Wound Care, Flexitouch System with Standard Wound Care
- Keywords
- Flexitouch system, FarrowWrap, venous stasis ulcer
- Medical subject headings
- Varicose Ulcer
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standard Wound CareDevice
Also called Farrow Wrap, Acticoat, Aquacel Ag, or Mepilex Ag foam dressings
Flexitouch System with Standard Wound CareDevice
Also called Flexitouch system, Farrow Wrap, Acticoat, Aquacel Ag, or Mepilex Ag foam dressings
| Study group | Role | What they receive |
|---|---|---|
| Standard Wound Care | Active comparator | Gentle wound ulcer cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (e.g Acticoat, Aquacel Ag, or Mepilex Ag foam dressings), reminding subjects of importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle range of motion exercises through the day. The FarrowWrap Classic device is applied over the dressing to achieve suitable compression pressures as an important component of the standard treatment. Receives: Device: Standard Wound Care |
| Flexitouch system with Standard Wound Care | Active comparator | In addition to standard wound care, patients who have been randomized to this group will be provided a home Flexitouch unit. They will be given instructions to use it on a twice daily basis (FarrowWrap will be removed during the time they are using Flexitouch). The Flexitouch System works by applying dynamic low-pressure compression to the trunk and affected limbs using gentle, rhythmic massage action. Receives: Device: Flexitouch System with Standard Wound Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Wound Healing
Measured: 12 weeks
Secondary outcomes (1)
Reduction in Leg Volume
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2009 (estimated)
- Study startSep 2007
- Primary completionAug 2010
- Study completionAug 2010
Why it stopped: Lack of Enrollment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Venous UlcerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 8 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tactile Systems Technology, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Wade Farrow, MD, Principal investigator, Wound Healing and Hyperbaric CenterSunday Hoy, JD, Study director, Tactile Systems Techonology Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00847002
- Sponsor's protocol ID
- FWFT07312007
- Status last verified
- Jan 2020
- First submitted
- 18 Feb 2009
- Last updated
- 12 Feb 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Feb 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pilot Randomized Trial of Flexitouch as an Adjunctive Treatment for Venous Ulcers
- ClinicalTrials.gov ID
- NCT00847002
- Acronym / sponsor ID
- FWFT07312007
- Conditions
- Venous Ulcer
- Keywords
- Flexitouch system, FarrowWrap, venous stasis ulcer
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Lack of Enrollment
- Enrolment
- 8 participants (actual)
- Lead sponsor
- Tactile Systems Technology, Inc.Industry (pharma, biotech, devices)
- Study start
- Sep 2007
- Primary completion
- Aug 2010 (actual)
- Study completion
- Aug 2010 (actual)
- First posted
- 19 Feb 2009 (estimated)
- Results
- Posted 25 Jul 2012
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a study to compare the healing process of venous stasis ulcers when the Flexitouch® system is added to the standard treatment of venous ulcers. We hypothesize that adding the Flexitouch® system to standard venous ulcer treatment will result in
- greater complete healing
- greater percentage reduction in ulcer area
- reduced time to complete healing, as compared to the use of standard treatment alone
- a greater reduction in affected leg volume as compared to standard treatment alone.
Detailed description
A pilot randomized trial of Flexitouch® as an adjunctive treatment for venous ulcers
Objectives To determine if the Flexitouch® compression therapy system, when added to standard venous ulcer (VU) treatment, results in: 1. Greater complete healing at 12 weeks as compared to standard treatment alone. 2. Greater percentage reduction in ulcer area at 12 weeks as compared to standard treatment alone. 3. Less time to complete healing as compared to standard treatment alone 4. A greater reduction in the leg volume of the affected leg
Hypothesis We hypothesize that adding the Flexitouch® system to standard venous ulcer treatment will result in
- greater complete healing, 2) greater percentage reduction in ulcer area 3) reduced time to complete healing, as compared to the use of standard treatment alone, and 4) a greater reduction in affected leg volume as compared to standard treatment alone.
Patient recruitment, eligibility, and exclusions Patients who present at our clinic with a venous leg ulcer, as judged by clinical presentation and history, will be recruited for participation in this research study. For this pilot study a total of 16 patients will be recruited.
Protocol and Procedures After verifying eligibility and administering an approved informed consent, patients will be randomized to one of the study arms (A or B). Study patients will be seen one or two times per week (per physician's discretion) for 12-weeks for standard wound care and treatment. For both groups, sustained compression will be achieved with the FarrowWrap™ Classic device. This device will be worn continuously except during the twice-weekly treatments and when Flexitouch therapy is being undertaken (Group B only). Group B will use Flexitouch at home every day (twice daily); Group A will not use Flexitouch. Once per week, treatment and parameter assessments will be undertaken as described below.
Standard Wound Care and Treatment Standard wound care treatment will include gentle wound ulcer cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (e.g Acticoat, Aquacel Ag, or Mepilex Ag foam dressings), reminding subjects of the importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle range of motion exercises through the day. The FarrowWrap Classic device is applied over the dressing to achieve suitable compression pressures as an important component of the standard treatment. For venous ulcer treatment it is applied at full stretch. The patient will be given instructions as to how to apply the FarrowWrap at home.
Flexitouch System and its Use Patients who have been randomized to Group B will be provided a home Flexitouch unit. They will be given instructions to use it on a twice daily basis. They will be instructed to remove the FarrowWrap during the time they are using Flexitouch. The Flexitouch System works by applying dynamic low-pressure compression to the trunk and affected limbs using gentle, rhythmic massage action. The system consists of a controller unit with four eight-port connectors and a garment set for the trunk and leg. The garments are placed around the trunk and affected limbs and are connected to the controller by a tubing harness. The controller inflates and deflates the air chambers within the garments in a pre-determined pattern to assist the lymphatics in moving the fluid into adjacent lymph node regions of the trunk. The controller inflates individual chambers in the garments for 1-3 seconds per inflation.
Potential Treatment modifications The patient's welfare, as determined by the principal investigator, will take precedence over any study procedures. Any interventions necessary for the patient's welfare will be undertaken as necessary.
Wound Photography The wound will be photographed using a digital camera with zoom capability supplied by the sponsor of this study. All photographs will be taken with the camera pointing directly down to the wound such that the angle between the camera and the plane-of-the wound is as near to 90o as possible. Flash will be avoided if there is adequate lighting. The vertical distance from the wound to the camera is not critical but a distance of about 20 cm will be used when possible. Prior to taking photographs, a suitable dimensional scale or calibration standard will be placed in contact with the skin near, but outside a wound margin. In the case of a one-dimensional scale, it will be placed above or below the wound, and positioned along the long dimension of the wound. A suitable calibration standard will be supplied by the sponsor of this study. The framing of the photo will be such as to include 1) the complete wound bed, 2) a small sampling of the surrounding periwound tissue and 3) the calibration standard or scale. The composed image, as viewed through the camera LCD viewport, will be as large as possible while still including the required elements. The camera will be oriented such that the horizontal dimension of the LCD viewport is parallel to the horizontal calibration scale on the leg.
Wound Tracing After photographing, the wound margins will be traced by placing a transparent grid over the wound. The grid is a commercial product (E-Z Graph) that is designed for this purpose. It consists of two layers; a bottom layer which is in contact with the wound and an upper layer on which tracing is done using a colored pen. The upper layer has a grid system with 1 x 1 cm squares imbedded into the material. After tracing the bottom layer is discarded. The patient's study ID, visit number and visit date are then recorded on a space provided on the upper tracing grid.
Assessment of Leg Volumes Leg volumes of both right and left legs from ankle to knee will be determined. This is done using a calibrated tape measure (Gulick-type) to measure circumferences at 4 cm intervals starting at the malleoulus and progressing toward the knee. From these circumference measurements, limb volumes will be determined using the well established truncated cone model together with a validated software algorithm. Using this method the wound assessor enters the circumferences into a standardized form and the appropriate volumes are automatically determined.
Assessment of Complete Wound Healing At each visit the wound will be carefully inspected by the Principal Investigator and the presence or absence of complete wound healing noted and recorded. For this study, wound healing will be considered to occur when the wound is fully covered with epithelium and there is no drainage. In addition, at each visit, a study-related case report form will be completed by the Principal Investigator to document various clinical features of the wound and to note any relevant study-related actions or events. This form will be embedded within password protected software so that most wound descriptors will be able to be entered and documented with a simple mouse click.
Analysis of Wound Areas and Related Parameters Wound Areas by Photo Images: The digital images of the wound will be coded by the Principal Investigator by suitably renaming each photographic image file with a unique identifier. He will keep a record of these coded file names and the group, patient, and visit date and number to which they correspond. A copy of each image file will be made and stored on a CD. The CD will be sent to a scientific advisor who works with the study sponsor. The advisor will be responsible for the analyses of the images, including the determination of wound areas via computerized planimetry and for subsequent data and statistical analyses. The analyst will blind as to which actual group the images correspond. At the completion of the data acquisition phase of the study, the analyst will be told which images belong to common groups, but he will still not know which of the common groups belong to which arm of the study. He will thus remain blind during the subsequent statistical analyses.
Wound Areas by Tracings: As a complementary comparison approach, wound areas will also be assessed from the wound tracings. The analyst will be supplied with copies of the coded tracings. The tracings will then be scanned and the wound areas determined by computerized digital planimetry as previously described. Areas determined by this method will serve as a check measurement and will be used as a backup in those cases (if any) in which photographic quality is inadequate.
Leg Volumes: In addition to photographs and tracings, the analyst will be supplied with coded electronic copies of the leg circumference forms. This data will be used to determine if, and to what extent, changes in leg volume or edema occur, and if there are differences in these parameters between groups A and B.
Wound Descriptors: A coded electronic version of the case report form, containing wound descriptor parameters data, will be supplied to the analyst. This information will be used primarily in the final analysis to summarize the clinical progression of the wounds.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard Wound Care | Active comparator | Device: Standard Wound CareGentle wound ulcer cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (e.g Acticoat, Aquacel Ag, or Mepilex Ag foam dressings), reminding subjects of importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle range of motion exercises through the day. The FarrowWrap Classic device is applied over the dressing to achieve suitable compression pressures as an important component of the standard treatment. |
| Flexitouch system with Standard Wound Care | Active comparator | Device: Flexitouch System with Standard Wound CareIn addition to standard wound care, patients who have been randomized to this group will be provided a home Flexitouch unit. They will be given instructions to use it on a twice daily basis (FarrowWrap will be removed during the time they are using Flexitouch). The Flexitouch System works by applying dynamic low-pressure compression to the trunk and affected limbs using gentle, rhythmic massage action. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Patient must be at least 18 years old
- The ulcer maximum length x its maximum width must be greater or equal to 0 cm2
- The ulcer must extend through both the epidermis and dermis, with no exposed tendon or bone.
- The ulcer must have been present for more than 1 month.
- The ulcer must be located below the knee.
Key exclusion criteria (21 listed)
- Exposed bone, tendon, or fascia
- Severe rheumatoid arthritis
- History of radiotherapy to the ulcer site
- Uncontrolled congestive heart failure
- Receiving corticosteroids or immune suppressive therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standard Wound CareAlso: Farrow Wrap, Acticoat, Aquacel Ag, or Mepilex Ag foam dressings | Device | Standard Wound Care |
| Flexitouch System with Standard Wound CareAlso: Flexitouch system, Farrow Wrap, Acticoat, Aquacel Ag, or Mepilex Ag foam dressings | Device | Flexitouch system with Standard Wound Care |
Primary outcome
Wound Healing
Time frame: 12 weeks
1 secondary outcome
Reduction in Leg Volume
Time frame: 12 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Feb 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Venous Ulcer
Recruiting
Dose-Response Structured Calf Muscle Pump Activation Strategies Versus Unsupervised Home Walks
Venous Ulcer of Leg
Recruiting
The GORE® VIABAHN® FORTEGRA Venous Stent Post-Approval Study
Venous Thromboses, Venous Disease
Not yet recruiting
Subcutaneous Dexpanthenol Administration and Wound Epithelialization
Chronic Wounds, Diabetic Foot Ulcer
RecruitingPhase 3
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
Venous Leg Ulcer (VLU)
Not yet recruitingPhase 1/2
Evaluating Autologous Platelet-Rich Fibrin Plasma for Chronic Lower Extremity Ulcers
Lower Extremity, Chronic Ulcers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wade Farrow, MD principal investigator
Wound Healing and Hyperbaric Center
Sunday Hoy, JD study director
Tactile Systems Techonology Inc.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Standard Wound Care and Flexitouch System with Standard Wound Care in people with Venous Ulcer, run by Tactile Systems Technology, Inc. at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 12 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 25 Jul 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Wound Healing (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Feb 2020; AzTrials last refreshed its copy on 28 Oct 2026.